Hi Lynn,
Well, chalk that Forbes article up to yet another example of a poor job done by the lay press who all too typically are woefully uninformed about AFIB, ablations and cardiology in general.
First of all, RAAFT-II was a follow up to the ground breaking RAAFT-1 study of some years ago that truly did include mostly just 'highly experienced' centers and top EPs and which showed a bigger gap, not surprisingly, in the benefits for a single ablation versus two years of AAR drugs and compared to this RAAFT-II study.
The RAAFT-II study resulted from the one valid criticism of RAAFT-I, in that it was felt that since RAAFT-1 reflected more the high volume truly very experienced operators results, for the most part, it was therefore not entirely representative of the average ablation experience. And so Dr Natale was recruited to oversee the study design of the new RAAFT-II protocol, and he largely drove the efforts to fully fund the study.
The key point here, and that is not even hinted at in either this Forbes' reporter's superficial review of RAAFT-II, but even by Hugh Calkins editorial (he must have just made an oversight in his comment ...), is that almost the entirety of the patients evaluated and followed in RAAFT-II were from average to lessor experienced EPs and were mostly from Canada and Europe and did NOT include any 'highly experienced' operators really at all!,
And yet Calkins even lets it slide in a comment in his editorial that mistakenly implies that RAAFT-II was also done by 'highly experienced' centers, as was the RAAFT-I study ... perhaps he was just honestly mistaken in the moment and was thinking of the RAAFT-1 study when he made that comment, which is surely understandable.
The truth is, that the centers that were selected for RAAFT-II, by design, did a maximum of no more than 200 AFIB ablations/year, or less, which is far from what I, as well as most leading EPs, would classify as 'highly experienced'. And especially from the EPs themselves working at such an average to modest volume center whose numbers would be even less for total ablations a year on an individual basis.
As many of you know, I list 200 procedures a year as the bare minimum for a given EP before I would recommend even considering them for an ablation process, with certain special exceptions. This is admittedly a conservative approach to help insure the best odds of both a great outcome with the shortest number of procedures needed to successfully complete one's ablation process, and to insure significantly greater odds of a low risk experience.
Indeed, Dr Calkins noted that caveat in his comments about the risks involved in AFIB ablation when he said 'considerations of operator experience can make a big difference in terms of both safety and efficacy of the procedure' in his longer review of the Desmukh study on 10 year complications of AF ablations in the US. I suspect Dr Calkins would take real issue with the way the slant that this article portrays AF ablation as a process for addressing AF.
And Lynn, you mentioned Dr Natale's involvement in RAAFT-II, just keep in mind that his efforts were strictly limited to the design and layout of the study and research funding alone. Not one single patient from RAAFT-II was ablated by Dr Natale, nor any of his mentored EPs at St Davids in Austin or CPMC in San Francisco. ... His centers were not directly involved in this second phase of RAAFT at all and were only listed because of his organizational and design efforts to set the guidelines of the study up to begin with.
Another key point to remember is that AF ablation IS a 'process' which we harp on all the time here. These two RAAFT I & II studies generally only look at a single ablation compared to a course of AAR drugs over the same time frame in comparing them, rather than long term drug use compared to a successful ablation 'process' long term.
As such, the actual reality as expressed by this average case RAAFT-II study reviewing only average run of the mill ablationist, mostly in Canada and Europe, and where adenosine and isoporterenol drug challenge of ablation lesions during the index ablation was still very rarely done through the duration of both of these studies, this also puts the ablation outcomes and their risks in the worse possible light and yet still there was a notable advantage even over just a two year maximum course of AAR drugs with a single ablation by an average run of the mill EPs for the most part!
If they had included even the result of even just 1.3 touch up ablations per patient during this two year period, the real world benefits of ablation over drugs, even with run of the mill average EPs, would have been much higher indeed.
It is unfortunate that no doubt well-meaning but under-informed medical journalist so often just get the superficial sound bites from such a study. And then, so often convey their skewed impression of the big picture and what the results imply to the public.
This is no news to the vast majority of us here who have had ablations and gone through an ablation process with a decent operator. We know first hand that an expert ablation process is often the single best medical decision we have made. And in the large majority of cases, has resulted in vastly improving our quality of life by a wide margin from the dim challenging days of walking on eggs shells waiting for the next episode of arrhythmia to throw a blanket over our lives again, and again, and again ... until we are worn down to the bone.
As for risks as well, such as tamponade or the dreaded esophageal fistula. The 4 tamponades out of 127 persons in RAAFT-II is definitely excessive and does not at all reflect anything close to the rates common with more elite ablationists at truly top tier centers.
Speaking of Dr Natale for example, as of two weeks ago when I last checked, he has never had an esophageal fistula in spite of the unprecedented many thousands of often challenging AFIB/Flutter ablations he has done over the years. His rate of cardiac tamponade is extremely low as well over his 18 years of both focal and PVAI-based ablations.
Quite a number of years ago, Natale's centers eventually stopped doing routine PV-Stenosis CT scans during the 3 month follow up post ablation, since those CT scans for stenosis had all come back negative for so long that there was no longer a viable rationale for continued CT testing ...
Certainly, minor to modest temporary complications or side effects do happen, even with Dr Natale. and for any doc it's true that they could do everything perfectly right and still have some unwanted effects and outcome from time to time, such is the nature of working on so many variable bodies and physiologies. But it's clear you most definitely stack the odds way in your favor by choosing a highly skilled operator as one of you top priorities.
This RAAFT-II report when evaluated alongside the RAAFT-I study is just one more confirmation for our near religious zeal in urging newcomers here not to compromise any more than is necessary for their circumstances and finances in choosing the most experienced and renowned ablationist they can find, it and is why I make no apologies for seeming so strict on that issue.
My fondest wish is for every single afibber who comes to our site, if in spite of their very best efforts at dietary, mineral repletion, life style management and stress reduction methods that we strongly support, they still have continued arrhythmia ... to at least then learn enough to make their way to the very best EP they can find to increase their chances of having a great outcome.
It is not at all about interviewing a whole grab bag of ablationist and then just picking which doc happens to strike your fancy the best and gives you a good 'gut feel'.
So the reality of RAAFT-II is that while it is instructive in confirming the basic differences between going to generally more elite centers (RAAFT-I results) compared to more average centers (RAAFT-II results), and adds further reinforcement to our less compromising approach to EP selection here, it also shows a far from terrible outcome from most of the EPs in the RAAFT-II study, even though they typically might require an extra ablation or two to get to the level of the more experienced operator over a two year or more period compared to AAR drugs.
Hopefully, now that more and more Canadian and EU EPs will surely start adopting intra-procedural adenosine and Isuprel drug challenge as well as adopt the new Contact Force or low flow irrigated catheters and improved technology available now, even those among them that are average operator will improve their efficacy and risk numbers as well.
Shannon
Edited 3 time(s). Last edit at 08/09/2014 07:31PM by Shannon.